BPC 157 10mg + TB500 10mg

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

Reference-derived details for BPC 157 10mg + TB500 10mg.

• Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL total concentration (1.67 mg/mL of each peptide).
• Typical daily range: 600–1000 mcg total blend once daily (provides 300–500 mcg of each peptide).
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg total blend on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

• Route: Subcutaneous injection, once daily[5][6]. This blend contains equal amounts of BPC-157 and TB-500 (5 mg each); every dose drawn provides a 1:1 ratio of both peptides.
• Frequency: Inject once daily subcutaneously. This schedule uses 3.0 mL dilution to keep per-injection volumes ≥18 units for accurate measurement. Rotate injection sites systematically[7].
• For acute tissue injuries, some protocols suggest a higher initial loading phase[8][9]. This approach uses higher daily doses during the first 4 weeks before tapering to maintenance. Use with caution; robust human dose-finding data remain limited.
• Note: A small human case series combining BPC-157 and TB-500 for joint injuries reported improved outcomes at higher combined doses (4 mg BPC + 6 mg TB-500 intra-articular) compared to lower doses[8]. However, systemic subcutaneous protocols typically use the ranges above. Treatment duration is generally limited to 8–12 weeks before cycling off to evaluate response[9].

Supplies Needed

Plan based on an 8–16 week daily protocol with phased dosing (averaging ~700 mcg/day over the cycle).

• Peptide Vials (BPC-157 + TB-500, 10 mg blend each):
• Peptide Vials (BPC-157 + TB-500, 10 mg blend each):: 8 weeks ≈ 4 vials
• Peptide Vials (BPC-157 + TB-500, 10 mg blend each):: 12 weeks ≈ 6 vials
• Peptide Vials (BPC-157 + TB-500, 10 mg blend each):: 16 weeks ≈ 8 vials
• Insulin Syringes (U-100):
• Insulin Syringes (U-100):: Per week: 7 syringes (1/day)
• Insulin Syringes (U-100):: 8 weeks: 56 syringes
• Insulin Syringes (U-100):: 12 weeks: 84 syringes
• Insulin Syringes (U-100):: 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100-count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100-count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support tissue repair, wound healing, and recovery from musculoskeletal injuries[1][3]. Open source
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if needed).
• Dose Range: 600–1000 mcg total blend daily (300–500 mcg of each peptide).
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily phased approach.

• Start: 600 mcg total daily (300 mcg each peptide) for Weeks 1–2.
• Loading: Increase to 800 mcg daily for Weeks 3–4.
• Maintenance: Return to 600 mcg daily for Weeks 5–8+.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.

Storage Instructions

Proper storage preserves peptide quality and stability.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4–6 weeks; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Both peptides are not approved for routine human use (sold for research purposes) and are banned in competitive sports[10]. Open source
• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[7]. Open source
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.

How This Works

BPC-157 is a stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects across gastrointestinal, musculoskeletal, and neurological tissues in preclinical models[1][2]. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies[11].

• TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, wound healing, and anti-inflammatory responses[3][4]. It is well-tolerated in animal and early clinical studies, even at multi-milligram doses[12].
• Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 for its trophic and anti-inflammatory effects, and TB-500 for enhanced cell migration and angiogenesis[8].

Potential Benefits & Side Effects

Observations from preclinical and limited clinical literature.

• May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries[1][5]. Open source
• Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157[2]. Open source
• TB-500 promotes wound healing and may reduce scarring through enhanced cell migration[3]. Open source
• Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
• No significant toxicity has been documented up to high doses in animal studies[11][12]. Open source

Injection Technique

General subcutaneous guidance from clinical best-practice resources[6][7].

• Clean the vial stopper and skin with alcohol; allow to dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[13]. Open source
• Do not aspirate for subcutaneous injections; inject slowly and steadily[13]. Open source
• Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms, flank) to avoid lipohypertrophy[7]. Open source
• Apply gentle pressure post-injection; do not rub the site.

Lifestyle Factors

Complementary strategies for optimal recovery outcomes.

• Prioritize adequate protein intake (1.6–2.2 g/kg body weight) to support tissue repair.
• Follow appropriate rehabilitation protocols for any injuries being addressed.
• Ensure adequate sleep (7–9 hours) to optimize recovery and tissue regeneration.
• Manage inflammation through balanced nutrition and stress reduction techniques.

Recommended Source

We recommend Pure Lab Peptides for high-purity BPC-157 + TB-500 (10 mg blend).

• High-purity, third-party-tested lots with batch COAs.
• Consistent, ISO-aligned handling and documentation.
• Reliable fulfillment to maintain cold-chain integrity.
• Shop at Pure Lab Peptides

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

• Do not start, stop, combine, or change a protocol based only on website content.
• Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference source used for this protocol page.

• BPC-157 + TB-500 (10mg Blend Vial) Open source
• Peptify Reconstitution Guide